ARKG Holdings of Personalis (PSNL) - Updated Daily
Join Premium Plan
Key Statistics
Statistics
Clinical Trials (0)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $8.29 |
| ⚖️Weighting | 🧢Market Cap |
| 1.21% | $372.64m |
| 🏋🏿♂️Weight Rank In ARKG | 🧮Price to Sales |
| 30 | 4.36 |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 73 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
| $17.70 | 11.46% |
| Description | |
|---|---|
| Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The PersonalisClinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited. | |
| Website | |
| www.personalis.com |
Research Notes and Commentary for PSNL
August 10, 2020
Personalis (PSNL) Is Pioneering Population-Sequencing-as-a-Service
See Section #4March 22, 2020